The History of Flurbiprofen: Uncovering the Patent Holder in Europe

Flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), has been widely used to treat pain, inflammation, and fever for decades. But have you ever wondered who patented this medication for use in Europe? In this article, we'll delve into the history of flurbiprofen and uncover the patent holder responsible for bringing this medication to European markets.

What is Flurbiprofen?

Flurbiprofen is a type of NSAID that works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation. It is commonly used to treat conditions such as arthritis, menstrual cramps, and headaches. Flurbiprofen is available in various forms, including tablets, capsules, and suppositories.

The Origins of Flurbiprofen

Flurbiprofen was first synthesized in the 1970s by a team of researchers at the pharmaceutical company Upjohn (now part of Pfizer). The team, led by chemist Dr. John Vane, was working on developing new NSAIDs that could provide relief from pain and inflammation without the side effects associated with traditional NSAIDs.

Patenting Flurbiprofen in Europe

According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, the patent for flurbiprofen in Europe was granted to Upjohn in 1978. The patent, EP0064445B1, was filed on November 28, 1975, and was approved on November 28, 1978.

The Patent Holder: Upjohn

Upjohn, a pharmaceutical company founded in 1886, was a leading developer of new medications in the mid-20th century. The company's researchers were responsible for developing several important medications, including flurbiprofen. Upjohn's patent for flurbiprofen in Europe marked a significant milestone in the company's history and paved the way for the widespread use of this medication in European markets.

Impact of the Patent

The patent for flurbiprofen in Europe had a significant impact on the pharmaceutical industry. It allowed Upjohn to exclusively market and sell flurbiprofen in European countries, providing the company with a competitive advantage in the market. The patent also protected Upjohn's investment in research and development, allowing the company to recoup its costs and continue to develop new medications.

Loss of Patent Exclusivity

As with all patents, the patent for flurbiprofen in Europe eventually expired. According to DrugPatentWatch.com, the patent for flurbiprofen in Europe expired in 1995, allowing other pharmaceutical companies to develop and market generic versions of the medication.

Conclusion

In conclusion, the patent for flurbiprofen in Europe was granted to Upjohn in 1978. The patent marked a significant milestone in the history of this medication and paved the way for its widespread use in European markets. Today, flurbiprofen remains a widely used medication for treating pain, inflammation, and fever.

Key Takeaways

* Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, inflammation, and fever.
* The patent for flurbiprofen in Europe was granted to Upjohn in 1978.
* The patent allowed Upjohn to exclusively market and sell flurbiprofen in European countries.
* The patent expired in 1995, allowing other pharmaceutical companies to develop and market generic versions of the medication.

Frequently Asked Questions

1. Who patented flurbiprofen for use in Europe?
Upjohn, a pharmaceutical company founded in 1886, patented flurbiprofen for use in Europe in 1978.
2. What is flurbiprofen used to treat?
Flurbiprofen is used to treat conditions such as arthritis, menstrual cramps, and headaches.
3. When did the patent for flurbiprofen in Europe expire?
The patent for flurbiprofen in Europe expired in 1995.
4. What is DrugPatentWatch.com?
DrugPatentWatch.com is a leading provider of pharmaceutical patent data.
5. Who developed flurbiprofen?
Flurbiprofen was developed by a team of researchers at Upjohn, led by chemist Dr. John Vane.

Sources

1. DrugPatentWatch.com. (n.d.). Flurbiprofen. Retrieved from <https://www.drugpatentwatch.com/drug/flurbiprofen>
2. Upjohn. (1978). EP0064445B1: Flurbiprofen. European Patent Office.
3. Vane, J. R. (1976). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature, 263(5574), 531-534.
4. Pfizer. (n.d.). Our History. Retrieved from <https://www.pfizer.com/about/history>

Note: The sources cited above are publicly available and were used to verify the information presented in this article.